ABSTRACT
This concluding chapter sets out a vision for a more equitable, solidaristic, and care-centred personalised medicine (PM). Drawing on themes from across this book, it critiques the high costs, access barriers, and exclusionary tendencies of current PM models, proposing reforms to pharmaceutical innovation, data governance, and patient engagement. It highlights the potential of Social Pharmaceutical Innovation and mixed public–private approaches to improve affordability and address unmet needs, alongside solidaristic data governance frameworks that recognise both individual and collective rights. This chapter advocates shifting from ‘club goods’ to public goods through inclusivity, equity, and context-sensitive design, and calls for patient-centred care and meaningful public and patient involvement to counteract depersonalising, data-driven approaches. Recommendations include fostering adaptable, mid-scale infrastructures, supporting global capacity building, and embedding relational autonomy into PM practice. Ultimately, it argues for a ‘human scale’ PM that values discretion, context, and the common good, ensuring data informs but does not determine care, and sustaining humane futures for health innovation.
